GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
CN Stock MarketDetailed Quotes
600056 China Meheco Group
- 10.65
- +0.03+0.28%
Market Closed Jan 24 15:00 CST
15.93BMarket Cap17.69P/E (TTM)
10.68High10.57Low77.51KlotVolume10.60Open10.62Pre Close82.44MTurnover0.52%Turnover Ratio15.19P/E (Static)1.50BShares13.8852wk High1.37P/B15.93BFloat Cap9.4552wk Low11.68Limit Up1.50BShs Float31.11Historical High9.56Limit Down1.04%Amplitude-1.82Historical Low0.23Dividend TTM10.64Avg Price32.66KlotAsk2.18%Div YieldTTM100Lot Size41.87KlotBid
China Meheco Group News
Announcement on the pre-reduction of 2024 results
China Meheco Group (600056.SH): The net income for the year 2024 is expected to decrease by 68% to 45%.
Glory Network reported on January 24 that China Meheco Group (600056.SH) announced a reduction in the 2024 annual performance forecast. According to preliminary calculations by the financial department, it is expected that the net income attributable to shareholders of the listed company will be between 0.335 billion yuan and 0.576 billion yuan, representing a year-on-year decrease of 68% to 45%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 0.231 billion yuan and 0.472 billion yuan, which is a year-on-year decrease of 62% to 23%. This reduction in performance is primarily due to the impacts of domestic centralized procurement price reductions, increased market competition, and tightening international demand.
Meheco Unit's Flumazenil Injection Passes Consistency Evaluation
CMB International: With continued policy efforts, Bullish on the rebound of China Meheco Group's valuation.
Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a high-elasticity Industry, is expected to outperform the market in 2025.
China Meheco Group Co., Ltd.'s (SHSE:600056) Share Price Is Matching Sentiment Around Its Earnings
Meheco Unit's Angina Tablets Passes Chinese Drug Regulator's Consistency Evaluation
Meheco Unit's Sepsis Drug Included in China's Centralized Procurement Bid
China Meheco Group (600056.SH): Sodium piperacillin for injection is expected to be selected for centralized procurement.
China Meheco Group (600056.SH) announced that on December 12, 2024, its subsidiary in Hainan...
Meheco Receives Nod for Influenza Drug's Registration
China Meheco Group (600056.SH): Subsidiary obtained pharmaceutical registration approval.
On December 4th, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceuticals Co., Ltd. (referred to as "Tianfang Pharmaceuticals"), received an approved pharmaceutical registration certificate from the National Medical Products Administration for a phosphor oseltamivir capsule (referred to as "the pharmaceutical"). Phosphor oseltamivir is a precursor drug of its active metabolite (oseltamivir carboxylate), which is a selective neuraminidase inhibitor for influenza viruses.
Xinkangjie: From January to August 2024, the sales scale of pharmaceuticals in the china meheco group retail market reached 324.4 billion yuan, with a year-on-year growth of 1.4%.
In terms of distribution channels, the scale of retail pharmacies (including O2O) accounts for 87.0%, with a year-on-year growth rate of 0.3%; the scale of e-commerce B2C accounts for 13.0%, with a year-on-year growth rate of 9.6%, and the scale proportion has increased by 1.0% year-on-year, highlighting the importance of the channel.
Meheco Gets Supplementary Drug Approval for ADHD Drug
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.
China Meheco Gets Approval for Brain Trauma Surgery Drug
China Meheco Group (600056.SH): The hydrochloride tomoxetine capsules have received the approval notice for the supplementary pharmaceutical application.
Ge Longhui December 2nd | China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received two copies of the approval notice for supplementary application for the drug Tobramycin Hydrochloride Capsules issued by the National Medical Products Administration, indicating that the drug passed the evaluation of the consistency of generic drug quality and efficacy. Tobramycin Hydrochloride Capsules are used to treat attention deficit/hyperactivity disorder (ADHD) in children and adolescents. Currently, the original research product has been imported and launched in the domestic market.
China Meheco Group (600056.SH): Phosphorylcholine Sodium Injection passed the generic drug consistency evaluation.
Glory Holdings reported on November 29 that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received three "Pharmaceutical Supplement Application Approval Notices" approved and issued by the National Medical Products Administration for sodium cytidine diphosphate injection, which has passed the consistency evaluation of quality and efficacy for generic drugs. Sodium cytidine diphosphate injection is a drug that improves cellular metabolism and is used for consciousness disorders after acute cranial trauma and brain surgery.
China Meheco Group (600056.SH): Chongqing Huayi Pharmaceutical Group will unconditionally transfer 2% equity of Chongqing Pharmaceutical held by it to General Technology Group.
On November 28, Gelonhui: China Meheco Group (600056.SH) announced that on November 28, 2024, the company received a report from Chongqing Medicine regarding the 'Notification Letter' from Meheco Group. Chongqing Meheco Group has obtained the approval from the Chongqing State-owned Assets Supervision and Administration Commission for the free transfer of 2% equity of Chongqing Medicine Health Industry Co., Ltd. held by Chongqing Meheco Holding (Group) Company (Yuzi [2024] No. 544). The Chongqing State-owned Assets Supervision and Administration Commission has approved Chongqing Meheco Group to transfer its 2% equity in Chongqing Medicine to Universal Technology Group without any consideration.
China Meheco Group (600056.SH): plans to renew the office building lease.
格隆汇November 27th | china meheco group (600056.SH) announced that, in response to the company's operational needs and to meet the company's office requirements, the company's office address has been relocated to Floors 18-28, Block B, Universal Era Center at the beginning of 2023. Given that the lease term for 2024 is approaching its expiration date, the company, along with china medical insurance and china medical device, intend to renew the "Universal Era Center Lease Contract" with Universal Technology Group, renewing Floors 18-28, Block B of Universal Era Center at 1 courtyard, 1st district, 1 West Ying Street, Fengtai District, Peking as the office address. The pricing will be based on market prices and the pricing standards of similar office buildings in the surrounding area of Universal Era Center.
China Meheco Group Obtains Drug Registration for Antibiotic, Blood Pressure Medications
china meheco group (600056.SH): Clindamycin Phosphate Injection Obtained Drug Registration Certificate
GeLongHui, November 21st | China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Hainan General Kangli Pharmaceutical Co., Ltd., has received three Lincomycin Phosphate Injection "Pharmaceutical Registration Certificates" issued by the National Medical Products Administration. Lincomycin Phosphate Injection is mainly used for severe infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, staphylococci sensitive strains, and designated sensitive microorganisms.